On October 25, 2022 Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, reported the Company will release its third quarter 2022 financial results before the market opens on Tuesday, November 8, 2022 (Press release, Agenus, OCT 25, 2022, View Source [SID1234622356]). Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast
A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at View Source and via View Source

"The Road Taken" R&D Event
Agenus will host an in-person and virtual R&D event ("The Road Taken") on Saturday, November 12th, 2022, from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA. The event will feature insights from leading cancer immunologists who will share their collective and individual expertise on the current and future state of cancer immunotherapy, including a deep dive into the botensilimab data presented at SITC (Free SITC Whitepaper). Institutional investors, research analysts, and key opinion leaders are invited to attend the Event in-person and can RSVP by emailing [email protected]. To register for the live webcast, please click here.